Survey of autologous blood transfusion activity in England (2001)

Decreased Transfusion Requirements with Use of Acute Normovolemic Hemodilution in Open Aortic Aneurysm Repair

OBJECTIVES

Acute normovolemic hemodilution (ANH) is an operative blood conservation technique involving the removal and storage of patient blood after induction of anesthesia, while maintaining normovolemia with crystalloid and/or colloid replacement. Developed and used predominately in cardiac surgery, ANH has been applied to the vascular surgery population but data regarding impact on transfusion requirements in this population is limited. The objective of this study is to compare transfusion requirements and coagulopathy in patients undergoing open abdominal aortic aneurysm repair (oAAA) employing ANH to those receiving only product replacement as clinically indicated.

METHODS

This is a retrospective review of patients undergoing elective oAAA at a quaternary aortic referral center from 2017-2019. Those eligible for ANH, no active cardiac ischemia, no valvular disease, normal LV/RV function, CKD < stage 3, HCT > 38%, normal coagulation profile, were included in the study. Patient demographics and characteristics were collected as were operative variables including extent of aneurysm, clamp site, visceral/renal ischemia time, operative time, and transfusion requirements. Post-operative morbidity, mortality, and length of stay were analyzed. Patients with and without ANH were matched and compared. Continuous measures were analyzed with Wilcoxon rank sum tests and t-tests.

RESULTS

Over the study period, 209 oAAA were performed, 76 patients met inclusion criteria; 27 patients underwent ANH while 49 did not. Patients with ANH had less PRBC transfusion intraoperative (Median [25^th,75^th]: 0 [0,1] vs. 1[0,2] units, p=0.02), at 24 hours(0[0,1] vs. 1[0,2] units, p=0.008), at 48 hours (0[0,1] vs. 1[0,2], p=0.007) and throughout the admission (0[0,1] vs. 2[0,2], p=0.011). There was no difference in intraoperative platelet or cryoprecipitate transfusions. At 48-hours, ANH had significantly higher platelet counts (142 ±35.8 vs. 124±37.6 x10(3)/mcL, p=0.044), lower PTT, and lower INR. There was no difference in MI, RTOR, or mortality (1 death overall). ANH patients had shorter LOS (7.0±2.7 vs 8.8±4.8 days, p=0.041).

CONCLUSIONS

ANH during oAAA results in less intraoperative and post-operative PRBC with improved coagulation parameters and a shorter hospital LOS.

Perioperative red blood cell transfusion in orofacial surgery

In the field of orofacial surgery, a red blood cell transfusion (RBCT) is occasionally required during double jaw and oral cancer surgery. However, the question remains whether the effect of RBCT during the perioperative period is beneficial or harmful. The answer to this question remains challenging. In the field of orofacial surgery, transfusion is performed for the purpose of oxygen transfer to hypoxic tissues and plasma volume expansion when there is bleeding. However, there are various risks, such as infectious complications (viral and bacterial), transfusion-related acute lung injury, ABO and non-ABO associated hemolytic transfusion reactions, febrile non-hemolytic transfusion reactions, transfusion associated graft-versus-host disease, transfusion associated circulatory overload, and hypersensitivity transfusion reaction including anaphylaxis and transfusion-related immune-modulation. Many studies and guidelines have suggested RBCT is considered when hemoglobin levels recorded are 7 g/dL for general patients and 8-9 g/dL for patients with cardiovascular disease or hemodynamically unstable patients. However, RBCT is occasionally an essential treatment during surgeries and it is often required in emergency cases. We need to comprehensively consider postoperative bleeding, different clinical situations, the level of intra- and postoperative patient monitoring, and various problems that may arise from a transfusion, in the perspective of patient safety. Since orofacial surgery has an especially high risk of bleeding due to the complex structures involved and the extensive vascular distribution, measures to prevent bleeding should be taken and the conditions for a transfusion should be optimized and appropriate in order to promote patient safety.

A review of the application of autologous blood transfusion

Autologous blood transfusion (ABT) has been gradually attracting more attention due to the increasingly prominent problem of blood transfusion safety and blood shortage in recent years. With the rapid development of blood conservation techniques, blood component separation technology, blood transfusion medicine and a constant increase in clinical needs, ABT technology has been expanded and innovated to a large degree. In this study, the development of preoperative autologous blood donation (PABD), acute normovolemic hemodilution (ANH), intraoperative and postoperative autotransfusion, and other new technologies and theories are reviewed and existing questions are analyzed. Challenges and applications are also discussed in order to provide reference for peers.

Genomics and Blood Substitutes for 21st Century Europe (“EuroBloodSubstitutes”)

Blood transfusion is a medical intervention practised throughout the world. Blood is a biologically active material that can transmit diseases (e.g., HIV/AIDS and, perhaps, vCJD). People are becoming increasingly concerned about blood safety, despite improved screening and processing. Consequently, they are reluctant to donate blood or receive transfusions. Such problems can be solved by the development and incorporation into transfusion practices of so-called "blood substitutes" to replace some blood uses. The EuroBloodSubstitutes Project is funded by the European Union Framework 6 Programme to develop a technological platform for producing novel haem proteins and blood substitute components using micro-organisms (bacteria, fungi, yeast) as "cell factories." The Project will focus on bacteria (Escherichia coli), yeast (Pichia pastoris) and, longer-term, filamentous fungi (Aspergillus niger), all organisms used to synthesize commercially important products. The multi-centre Consortium consists of the Universities of (1) Nottingham (UK), (2) Essex (UK), (3) Denmark Technical (Denmark), (4) Lund (Sweden), (5) Milan (Italy), (6) Nancy (France), (7) Parma (Italy), (8) Rome "La Sapienza" (Italy), (9) Semmelweis (Hungary), together with (10) Alligator Bioscience, AB (Sweden), (11) LCC Engineering & Trading GmbH (Switzerland), (12) Scottish National Blood Transfusion Service (UK), and (13) Sanquin Bloodbank (The Netherlands). The EuroBloodSubstitutes Project will be informed by lay and professional stakeholders (e.g., clinicians, blood donors, patient groups, prescribers and policy makers). Outcomes of the Project are (1) the production of an information pack, decision aids and physician training aids, giving balanced overviews of the benefits and risks of transfusion of blood or potential substitutes, and (2) an interactive web site (http//:www.eurobloodsubstitutes.com) for information dissemination. This will improve knowledge and address misunderstandings about transfusion issues in a climate of changing patient expectations on blood safety and benefits of blood substitutes.

Acute perioperative normovolaemic haemodilution in major maxillofacial surgery

Extensive blood loss can occur when patients have major operations for head and neck neoplasia. The risks and costs of allogeneic blood transfusion have been well documented. Acute perioperative normovolaemic haemodilution (APNH) is a method of saving blood and autologous transfusion. The purpose of this study was to compare a group of patients having major head and neck operations who had APNH, with a historical group, to assess the need for allogeneic transfusion. Of the 21 patients who had APNH only one patient required allogeneic blood. In the historical group of 24 patients, 15 patients had required allogeneic blood (p=0.0001). APNH is an economic, safe and practical way of saving blood.

A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty

BACKGROUND

The optimum strategy for reducing allogeneic blood transfusion in patients undergoing total hip joint arthroplasty (THJA) is unknown.

STUDY DESIGN AND METHODS

The effectiveness of a comprehensive blood conservation algorithm (BCA) was evaluated by means of a cluster randomization trial. Thirty hospitals performing primary THJA were randomly assigned to implement the algorithm or to continue with usual care (UC). Subsequently, the institutional rate of allogeneic transfusion was determined for 60 consecutive patients who underwent surgery at each site. The BCA consisted of patient and provider education, hemoglobin-based recommendations for specific blood conservation strategies (recombinant human erythropoietin [rHuEPO] or autologous blood donation [ABD]) and transfusion guidelines. The main outcome measure was the institutional allogeneic transfusion rate.

RESULTS

One hospital withdrew consent after randomization, resulting in 14 hospitals assigned to BCA and 15 to UC. In the BCA arm, the institutional rates of rHuEPO use and ABD participation were 20.1 and 27.1 percent compared to 0.6 and 25.8 percent, respectively, in the UC arm. The allogeneic transfusion rate was substantially reduced in hospitals assigned to the BCA group (p = 0.02; absolute risk reduction, 9.6% [26.1% UC vs. 16.5% BCA]). Multivariate analysis of patient-level data showed that assignment to the UC arm was an independent risk factor for allogeneic transfusion (p = 0.037; odds ratio, 1.8; 95% confidence interval, 1.0-3.1) when adjusted for other prognostic factors. No differences were observed in the use of autologous blood.

CONCLUSION

A comprehensive approach to blood conservation was superior to UC for reducing allogeneic transfusion in patients undergoing THJA.

Recycling blood: sharing the benefits of cell salvage

This paper examines the service-wide costs to the English NHS that are associated with a Hospital Trust expanding the utilisation of cell salvage techniques as an alternative to using donated blood collected from volunteer donors. Costs in the respective NHS organisations should not be viewed in isolation. Significant savings can be realised by adopting a collaborative approach to expand the use of cell salvage techniques. In time, the associated increase in cell salvage utilisation will generate cost savings at the National Blood Service, with more immediate realisable savings arising within Hospital Trust budgets.